Drugs / NPC-14
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01918384 | Aug 2013 → Oct 2015 | Duchenne muscular dystrophy | Kobe University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPC-14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01918384 ↗ |
| Known as | Arbekacin | “Phase II Study of Nonsense Readthrough Compound NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy” NCT01918384 ↗ |
| Route | Intravenous | “Intravenous drip” NCT01918384 ↗ |